These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 24342775

  • 1. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, Serrano-Blanco A, Teba F, Usall J.
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):223-31. PubMed ID: 24342775
    [Abstract] [Full Text] [Related]

  • 2. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
    Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S.
    J Clin Psychiatry; 2011 Nov; 72(11):1552-7. PubMed ID: 21903021
    [Abstract] [Full Text] [Related]

  • 3. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
    Usall J, Huerta-Ramos E, Labad J, Cobo J, Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, Reyes JC, Roca M, RALOPSYCAT Group.
    Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.
    Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, Berk M, Dodd S, Fitzgerald PB, Davis SR.
    Psychoneuroendocrinology; 2010 Sep; 35(8):1142-7. PubMed ID: 20171784
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

  • 9. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M, Levi L, Burshtein S, Hagin M, Matei VP, Podea D, Micluția I, Tiugan A, Păcală B, Grecu IG, Noy A, Zamora D, Davis JM.
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [Abstract] [Full Text] [Related]

  • 10. [Additional effect of SERM: central nervous system].
    Honjo H.
    Clin Calcium; 2004 Oct; 14(10):69-72. PubMed ID: 15577134
    [Abstract] [Full Text] [Related]

  • 11. Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.
    Tharoor H, Goyal A.
    Arch Womens Ment Health; 2015 Oct; 18(5):741-2. PubMed ID: 26189131
    [Abstract] [Full Text] [Related]

  • 12. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
    Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB.
    Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):961-6. PubMed ID: 11535548
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Specificity proteins 1 and 4 in peripheral blood mononuclear cells in postmenopausal women with schizophrenia: a 24-week double-blind, randomized, parallel, placebo-controlled trial.
    Vila È, Huerta-Ramos E, Núñez C, Usall J, Ramos B.
    Eur Arch Psychiatry Clin Neurosci; 2019 Dec; 269(8):941-948. PubMed ID: 30167782
    [Abstract] [Full Text] [Related]

  • 15. Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia.
    Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, O'Donnell M, Galletly C, Liu D, Balzan R, Short B, Pellen D, Curtis J, Carr VJ, Kulkarni J, Schofield PR, Weickert CS.
    Mol Psychiatry; 2015 Jun; 20(6):685-94. PubMed ID: 25980345
    [Abstract] [Full Text] [Related]

  • 16. Adjunctive Raloxifene and Isradipine Improve Cognitive Functioning in Patients With Schizophrenia: A Pilot Study.
    Vahdani B, Armani Kian A, Esmaeilzadeh A, Zenoozian S, Yousefi V, Mazloomzadeh S.
    J Clin Psychopharmacol; 2020 Jun; 40(5):457-463. PubMed ID: 32796392
    [Abstract] [Full Text] [Related]

  • 17. Pharmacogenetic study of the effects of raloxifene on negative symptoms of postmenopausal women with schizophrenia: A double-blind, randomized, placebo-controlled trial.
    Labad J, Martorell L, Huerta-Ramos E, Cobo J, Vilella E, Rubio-Abadal E, Garcia-Pares G, Creus M, Núñez C, Ortega L, Miquel E, RALOPSYCAT Group, Usall J.
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1683-9. PubMed ID: 27546373
    [Abstract] [Full Text] [Related]

  • 18. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S, Farias ML, Luebbert H, Gomez G, Yabur JA, Quail DC, Turbi C, Kayath MJ, Almeida MJ, Mönnig E, Nickelsen T.
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Raloxifene affects brain activation patterns in postmenopausal women during visual encoding.
    Neele SJ, Rombouts SA, Bierlaagh MA, Barkhof F, Scheltens P, Netelenbos JC.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1422-4. PubMed ID: 11238542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.